Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease

World Journal of Gastroenterology

Volumn 20, Issue 13, 2014, Pages 3609-3614

  Thomas, Diamantis ^a   Gazouli, Maria ^a   Karantanos, Theodoros ^a   Rigoglou, Stella ^a   Karamanolis, Georgios ^b   Bramis, Konstantinos ^a   Zografos, George ^a   Theodoropoulos, George E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Crohn's disease; Infliximab; Polymorphisms; Treatment response

Indexed keywords

C REACTIVE PROTEIN; GENOMIC DNA; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER; CNTN5 PROTEIN, HUMAN; CONTACTIN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT RESPONSE; ADOLESCENT; ALLELE; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; ENDOSCOPY; GENETIC POLYMORPHISM; GENETICS; GREECE; INFLAMMATION; METABOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLONOSCOPY; CONTACTINS; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; ENDOSCOPY; FEMALE; GENOTYPE; GREECE; HUMANS; INFLAMMATION; MALE; POLYMORPHISM, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84897561317     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i13.3609     Document Type: Article

References (35)

1. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-653 [PMID: 18550004 DOI: 10.1016/j.cgh.2008.03.014]
2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962]
3. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65 [PMID: 17241859]
4. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017-1024; quiz 976 [PMID: 16843733]
5. Schreiber S, Reinisch W, Colombel JF, Sandborn W, Hommes D, Li J, Kent J, Pollack P. Early Crohn's disease shows high levels of remission to therapy with adalimumab: subanalysis of charm. Gastroenterology 2007; 132: A-147 [DOI: 10.1016/S1873-9954(07)70190-8]
6. Weinberg AM, Rattan S, Lewis JD, Su C, Katzka DA, Deren J. Strictures and response to infliximab in Crohn's disease. Am J Gastroenterol 2002; 97: S255
7. Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002; 97: 2350-2356 [PMID: 12358255]
8. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-824 [PMID: 12190096]
9. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120: 1347-1355 [PMID: 11313304]
10. Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20: 303-310 [PMID: 15274667]
11. López-Hernández R, Valdés M, Campillo JA, Martínez-Garcia P, Salama H, Salgado G, Boix F, Moya-Quiles MR, Minguela A, Sánchez-Torres A, Miras M, Garcia A, Carballo F, Álvarez-López MR, Muro M. Genetic polymorphisms of tumour necrosis factor alpha (TNF-α) promoter gene and response to TNF-α inhibitors in Spanish patients with inflammatory bowel disease. Int J Immunogenet 2014; 41: 63-68 [PMID: 23590430 DOI: 10.1111/iji.12059]
12. Mascheretti S, Hampe J, Kühbacher T, Herfarth H, Krawczak M, Fölsch UR, Schreiber S. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2: 127-136 [PMID: 12049175]
13. Niess JH, Klaus J, Stephani J, Pflüger C, Degenkolb N, Spaniol U, Mayer B, Lahr G, von Boyen GB. NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy. Dig Dis Sci 2012; 57: 879-886 [PMID: 22147245 DOI: 10.1007/s10620-011-1977-3]
14. Weiss B, Shamir R, Bujanover Y, Waterman M, Hartman C, Fradkin A, Berkowitz D, Weintraub I, Eliakim R, Karban A. NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared with adults with Crohn's disease. J Pediatr 2004; 145: 208-212 [PMID: 15289769]
15. Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123: 106-111 [PMID: 12105838]
16. Lacruz-Guzmán D, Torres-Moreno D, Pedrero F, Romero-Cara P, García-Tercero I, Trujillo-Santos J, Conesa-Zamora P. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis. Eur J Clin Pharmacol 2013; 69: 431-438 [PMID: 22960943 DOI: 10.1007/s00228-012-1389-0]
17. Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR, Lee AT, Huizinga TW, Allaart R, Barton A, Mariette X, Miceli CR, Criswell LA, Tak PP, de Vries N, Saevarsdottir S, Padyukov L, Bridges SL, van Schaardenburg DJ, Jansen TL, Dutmer EA, van de Laar MA, Barrera P, Radstake TR, van Riel PL, Scheffer H, Franke B, Brunner HG, Plenge RM, Gregersen PK, Guchelaar HJ, Coenen MJ. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1375-1381 [PMID: 23233654 DOI: 10.1136/annrheumdis-2012-202405]
18. Ogawa J, Kaneko H, Masuda T, Nagata S, Hosoya H, Watanabe K. Novel neural adhesion molecules in the Contactin/F3 subgroup of the immunoglobulin superfamily: isolation and characterization of cDNAs from rat brain. Neurosci Lett 1996; 218: 173-176 [PMID: 8945756]
19. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429 [PMID: 12167685]
20. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6; discussion 16-19 [PMID: 2617184]
21. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514 [PMID: 6102236]
22. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667-671 [PMID: 10536324]
23. Papmichael K, Gazouli M, Karakoidas C, Panayotou I, Roma-Giannikou E, Mantzaris JG. Association of TNF and FcγRIIIA gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients. Annal Gastroenterol 2011; 24: 35-40
24. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667 [PMID: 18295023 DOI: 10.1016/S0140-6736(08)60304-9]
25. Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013; 19: 2098-2110 [PMID: 23860567 DOI: 10.1097/ MIB.0b013e31829936c2]
26. Nogueira IM, Miszputen SJ, Ambrogini Jr O, Artigiani-Neto R, Carvente CT, Zanon MI. Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin. Arq Gastroenterol 2013; 50: 130-137 [PMID: 23903623]
27. Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C. A systematic review and economic evaluation of the use of tumour necrosis factoralpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess 2011; 15: 1-244 [PMID: 21291629 DOI: 10.3310/hta15060]
28. Magro F, Rodrigues-Pinto E, Santos-Antunes J, Vilas-Boas F, Lopes S, Nunes A, Camila-Dias C, Macedo G. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis 2014; 8: 129-136 [PMID: 23932786 DOI: 10.1016/j.crohns.2013.07.005]
29. Medrano LM, Taxonera C, Márquez A, Barreiro-de Acosta M, Gómez-García M, González-Artacho C, Pérez-Calle JL, Bermejo F, Lopez-Sanromán A, Martín Arranz MD, Gisbert JP, Mendoza JL, Martín J, Urcelay E, Núñez C. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. Hum Immunol 2014; 75: 71-75 [PMID: 24121042 DOI: 10.1016/j.humimm.2013.09.017]
30. Moroi R, Endo K, Kinouchi Y, Shiga H, Kakuta Y, Kuroha M, Kanazawa Y, Shimodaira Y, Horiuchi T, Takahashi S, Shimosegawa T. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 2013; 65: 265-271 [PMID: 23358932 DOI: 10.1007/s00251-013-0679-8]
31. Mesko B, Poliska S, Váncsa A, Szekanecz Z, Palatka K, Hollo Z, Horvath A, Steiner L, Zahuczky G, Podani J, Nagy AL. Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med 2013; 5: 59 [PMID: 23809696]
32. Denis MA, Reenaers C, Fontaine F, Belaïche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007; 13: 1100-1105 [PMID: 17508418]
33. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn' s disease. N Engl J Med 2010; 362: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]
34. Querol L, Nogales-Gadea G, Rojas-Garcia R, Martinez-Hernandez E, Diaz-Manera J, Suárez-Calvet X, Navas M, Araque J, Gallardo E, Illa I. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013; 73: 370-380 [PMID: 23280477 DOI: 10.1002/ana.23794]
35. Derfuss T, Parikh K, Velhin S, Braun M, Mathey E, Krumbholz M, Kümpfel T, Moldenhauer A, Rader C, Sonderegger P, Pöllmann W, Tiefenthaller C, Bauer J, Lassmann H, Wekerle H, Karagogeos D, Hohlfeld R, Linington C, Meinl E. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci USA 2009; 106: 8302-8307 [PMID: 19416878 DOI: 10.1073/pnas.0901496106]